Earnings Ahead

BIIB - Biogen Inc

156 0.57 0.37

Biogen Inc

Biogen Inc

About

Profile

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies


Headquarters

Cambridge, Massachusetts, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

BIIB



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Biogen swings to Q3 growth after Reata acquisition (update)
  • Biogen Non-GAAP EPS of $4.36 beats by $0.37, revenue of $2.53B beats by $130M
  • Biogen Q3 2023 Earnings Preview
  • Sage Therapeutics falls after stock offering, Q3 miss
  • Eisai sees a sharp rise in patients on Biogen-partnered Alzheimer’s drug
  • Earnings week ahead: Disney, AMC, Plug Power, Lucid, Realty Income and more
  • Catalyst Watch: Disney earnings, Moderna AI event, Powell IMF speech and Las Vegas strike threat
  • Pharma, PBMs spar over rising drug costs amid public scrutiny
  • Biogen says new Leqembi formulation better than IV version
  • Biogen updates Phase 1 data for Ionis-partnered Alzheimer’s drug
  • U.S. to expand access to PET imaging scans for Alzheimer's disease diagnosis
  • FDA approves Biogen’s biosimilar to Roche's arthritis drug Actemra
  • Biogen/ Eisai Alzheimer’s therapy Leqembi approved in Japan
  • These companies set to benefit from sales of Biogen Alzheimer's med Leqembi
  • Reata shareholders clear buyout deal with Biogen
  • Catalyst watch: Microsoft, Amazon, Oracle, and Intel to Hold High-Profile Events
  • Intas reportedly readying bid of up to $1B for Biogen biosimilars unit
  • Reata Pharmaceuticals climbs as HSR waiting period for sale to Biogen expired
  • HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead
  • Catalyst Watch: Arm IPO, Apple event, and Senate AI Forum with Musk, Zuckerberg, and Gates

Earnings History

Date EPS / Forecast Revenue / Forecast
February 3, 2022 3.39 / 3.35 2.73B / 2.62B Beat!
October 20, 2021 4.77 / 4.09 2.78B / 2.67B Beat!
July 22, 2021 5.68 / 4.55 2.78B / 2.61B Beat!
April 22, 2021 5.34 / 4.98 2.69B / 2.65B Beat!
February 3, 2021 4.58 / 4.79 2.85B / 2.8B Beat!
October 21, 2020 8.84 / 8.09 3.38B / 3.33B Beat!
July 22, 2020 10.26 / 8.02 3.68B / 3.43B Beat!
April 22, 2020 9.14 / 7.72 3.53B / 3.42B Beat!
January 30, 2020 8.34 / 8.03 3.67B / 3.54B Beat!
October 22, 2019 9.17 / 8.3 3.6B / 3.54B Beat!
July 23, 2019 9.15 / 7.53 3.62B / 3.47B Beat!
April 24, 2019 6.98 / 6.97 3.49B / 3.4B Beat!
January 29, 2019 6.99 / 6.73 3.53B / 3.39B Beat!
October 23, 2018 7.4 / 6.78 3.44B / 3.33B Beat!
July 24, 2018 5.8 / 5.21 3.36B / 3.25B Beat!
April 24, 2018 6.05 / 5.93 3.13B / 3.15B
January 25, 2018 5.26 / 5.45 3.31B / 3,080M Beat!
October 24, 2017 6.31 / 5.73 3.08B / 3,044M Beat!
July 25, 2017 5.04 / 5.62 3.08B / 2.81B Beat!
April 25, 2017 5.2 / 4.6 2.81B / - Beat!
January 26, 2017 5.04 / 5.01 2.87B / 2.94B
Date Price Open High Low Vol Change
Nov 20 155.99 155.03
156.15
153.63
1.6M 0.36%
Nov 19 155.43 157.02
157.9
155.28
1.3M -1.59%
Nov 18 157.94 158.19
160.11
157.4
1.6M -1.28%
Nov 15 159.99 165.46
166.34
159.6
1.9M -2.97%
Nov 14 164.89 165
175.86
163.35
3.2M -0.54%
 
Nov 13 165.79 167.74
168.98
165.53
1.4M -1.48%
Nov 12 168.28 171.36
171.61
167.71
1.4M -2.18%
Nov 11 172.03 173.92
173.92
171.11
1.5M -0.58%
Nov 8 173.04 173.58
175.2
171.57
1.6M -0.51%
Nov 7 173.92 175.69
176.95
172.8
1.4M -0.28%
Nov 6 174.4 176.87
179.2
173.66
1.8M -1.43%
Nov 5 176.93 172.71
177.25
170.72
2.5M 1.97%
Nov 4 173.52 173.22
174.85
170.71
2.5M -0.16%
Nov 1 173.79 173.65
175.99
173.14
1.5M -0.12%
Oct 31 174 178.11
179.48
173.88
1.8M -3.96%
Oct 30 181.18 184.63
185
177.93
1.6M -1.25%
Oct 29 183.47 184.82
187.28
183.19
1.3M -0.83%
Oct 28 185.01 182.48
185.6
181.73
1.9M 1.83%
Oct 25 181.69 185.7
187.58
181.24
1.7M -1.18%
Oct 24 183.86 184.79
185.72
183.28
1.1M 0.48%
Oct 23 182.98 184.88
185.82
182.11
978K -1.57%
Oct 22 185.9 183.81
186.54
182.8
831K 0.68%
Oct 21 184.65 190.16
190.4
184.02
1.3M -2.9%
Oct 18 190.16 188.22
191.19
187.94
928K 0.32%
Oct 17 189.55 188.55
190.19
187.7
729K 0.29%
Oct 16 189 191.68
192.16
188.9
985K -1.33%
Oct 15 191.55 191.87
194.13
190.67
1.4M -0.01%
Oct 14 191.56 188.59
191.96
186.61
1.3M 1.69%
Oct 11 188.38 189
189.43
186.91
1.4M -0.11%
Oct 10 188.59 184.56
188.88
184.3
1.3M 1.52%
Oct 9 185.76 182.46
185.8
181.31
1.2M 1.90%
Oct 8 182.3 182.73
183.55
181.31
1.2M -0.57%
Oct 7 183.34 184.76
185.93
182.48
984K -1.26%
Oct 4 185.68 186.68
186.8
183.82
1.1M 0.49%
Oct 3 184.78 187.21
188.14
183.56
2.0M -2.1%
Oct 2 188.74 190.08
191.86
188.05
1.5M -1.08%
Oct 1 190.8 194.61
195
190.27
2.2M -1.57%
Sep 30 193.84 193.36
194.48
192.28
990K -0.43%
Sep 27 194.67 194.49
197.7
193.98
710K 0.55%
Sep 26 193.6 191.17
193.73
190.5
818K 2.40%
Sep 25 189.07 193.84
194.56
188.78
1.5M -2.6%
Sep 24 194.12 199.99
199.99
193.54
1.2M -0.86%
Sep 23 195.81 199.2
199.2
195.67
1.3M -1.78%
Sep 20 199.36 200.01
200.37
196.96
3.8M -1.03%
Sep 19 201.44 200.57
204.18
200.11
1.1M 1.95%
Sep 18 197.59 198.13
199.78
196.8
671K -0.31%
Sep 17 198.21 199.83
202.79
197.09
924K -0.69%
Sep 16 199.58 197.26
199.74
194.75
1.0M 2.02%
Sep 13 195.63 197.66
197.7
192.25
1.1M -1.14%
Sep 12 197.89 199.05
199.26
194.9
852K -0.6%
Sep 11 199.09 198.95
199.28
196.02
795K -0.77%
Sep 10 200.64 199.49
201.19
197.82
557K 0.69%
Sep 9 199.27 200.44
201.06
198.11
883K -0.77%
Sep 6 200.81 202.53
203.24
198.55
835K -0.49%
Sep 5 201.8 205.19
205.19
198.19
1.1M -1.54%
Sep 4 204.95 205.72
206.5
203.53
785K 0.05%
Sep 3 204.84 204.22
206.7
203.5
892K 0.04%
Aug 30 204.76 205.82
205.88
202.85
879K -0.03%
Aug 29 204.82 206
206.38
202.76
520K 0.30%
Aug 28 204.2 203.76
204.72
202.93
637K 0%